This post is from a suggested group
Addressing a Silent Epidemic: Analysis of the Dry Age-Related Macular Degeneration (AMD) Market
The Dry Age-Related Macular Degeneration (AMD) Market is poised for significant transformation, driven by a dire lack of treatment options and the rapidly increasing global elderly population, the primary demographic affected by this debilitating eye disease. Dry AMD, the most common form of AMD, leads to central vision loss and currently has no widely available cure or definitive pharmacological intervention to reverse its progression. The market is thus defined by the immense unmet clinical need, creating a massive incentive for pharmaceutical and biotechnology companies to invest heavily in novel therapeutic research. Current market activity is concentrated in the early diagnosis segment, including advanced retinal imaging technologies like Optical Coherence Tomography (OCT) and fundus autofluorescence, which are crucial for early detection and monitoring. The market growth is also supported by the increasing adoption of nutritional supplements and vitamins…